Advances in the Treatment of Metabolism-related Fatty Liver Disease with Curcumin-based Drugs

The incidence of metabolic-associated fatty liver disease(MAFLD) has been increasing year by year in recent years and has become the most common chronic liver disease threatening human health, and there are no clinically effective drugs approved for the treatment of MAFLD. Several in vitro and in vivo studies have demonstrated that curcumin may improve MAFLD by affecting fatty acid metabolism, insulin resistance, liver inflammation, and intestinal flora processes. This paper summarizes the progress of curcumin-based drugs for MAFLD in animal studies and clinical studies in the past 5 years, with the aim of providing more possibilities for curcumin-based drugs for the treatment of metabolic-related diseases.